HK1157009A1 - Prion protein ligands and methods of use - Google Patents

Prion protein ligands and methods of use

Info

Publication number
HK1157009A1
HK1157009A1 HK11111159.1A HK11111159A HK1157009A1 HK 1157009 A1 HK1157009 A1 HK 1157009A1 HK 11111159 A HK11111159 A HK 11111159A HK 1157009 A1 HK1157009 A1 HK 1157009A1
Authority
HK
Hong Kong
Prior art keywords
prion protein
ligands
prion
methods
protein ligands
Prior art date
Application number
HK11111159.1A
Other languages
English (en)
Chinese (zh)
Inventor
David J Hammond
Julia T Lathrop
Larisa Cervenakova
Ruben G Carbonell
Original Assignee
北卡羅來納州立大學
病原體切除與診斷科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北卡羅來納州立大學, 病原體切除與診斷科技公司 filed Critical 北卡羅來納州立大學
Publication of HK1157009A1 publication Critical patent/HK1157009A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11111159.1A 2002-12-03 2011-10-19 Prion protein ligands and methods of use HK1157009A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43042302P 2002-12-03 2002-12-03

Publications (1)

Publication Number Publication Date
HK1157009A1 true HK1157009A1 (en) 2012-06-22

Family

ID=32469468

Family Applications (4)

Application Number Title Priority Date Filing Date
HK06109265.3A HK1088948A1 (en) 2002-12-03 2006-08-22 Prion protein ligands and methods of use
HK09101031A HK1124388A1 (en) 2002-12-03 2009-02-05 Prion protein ligands and methods of use
HK11111172.4A HK1157010A1 (en) 2002-12-03 2011-10-19 Prion protein ligands and methods of use
HK11111159.1A HK1157009A1 (en) 2002-12-03 2011-10-19 Prion protein ligands and methods of use

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK06109265.3A HK1088948A1 (en) 2002-12-03 2006-08-22 Prion protein ligands and methods of use
HK09101031A HK1124388A1 (en) 2002-12-03 2009-02-05 Prion protein ligands and methods of use
HK11111172.4A HK1157010A1 (en) 2002-12-03 2011-10-19 Prion protein ligands and methods of use

Country Status (15)

Country Link
US (3) US7863411B2 (xx)
EP (4) EP2317317B1 (xx)
JP (1) JP4485367B2 (xx)
CN (3) CN1739029B (xx)
AT (1) ATE529744T1 (xx)
AU (2) AU2003302500B2 (xx)
CA (2) CA2836951C (xx)
DK (4) DK1953551T3 (xx)
ES (4) ES2460641T3 (xx)
HK (4) HK1088948A1 (xx)
IL (3) IL168904A (xx)
MX (2) MXPA05005920A (xx)
NZ (3) NZ540417A (xx)
PT (4) PT2317317E (xx)
WO (1) WO2004050851A2 (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
MXPA03011000A (es) * 2001-05-31 2004-02-27 Arete Associates Metodo de sensor de proteinas deformadas.
EP2317317B1 (en) * 2002-12-03 2014-11-26 North Carolina State University Prion protein ligands and methods of use
EP1616036A4 (en) * 2003-04-14 2007-03-21 Pathogen Removal And Diagnosti PROCESS FOR IDENTIFYING LIGANDS SPECIFIC TO STRUCTURAL FORMS OF PROTEINS
AU2004264953B2 (en) 2003-08-13 2009-07-23 Novartis Vaccines And Diagnostics, Inc. Prion-specific peptide reagents
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
AU2006214463B2 (en) * 2005-02-15 2012-08-30 Presympto, Inc. Method for detecting misfolded proteins and prions
JP5209477B2 (ja) 2005-09-09 2013-06-12 ノバルティス アーゲー プリオンに特異的なペプトイド試薬
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2397441T5 (es) 2006-02-13 2022-09-14 Daiichi Sankyo Co Ltd Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
WO2008005960A2 (en) * 2006-07-07 2008-01-10 Pall Corporation Prion processing
US8673579B2 (en) * 2006-07-28 2014-03-18 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
EP2122367A2 (en) * 2007-01-12 2009-11-25 allprion AG Method for removing prion protein
EP2282753A1 (en) * 2008-04-30 2011-02-16 Novartis AG Assay for pathogenic conformers
HUE047376T2 (hu) 2009-04-15 2020-04-28 Abraxis Bioscience Llc Prionmentes nanorészecske-készítmények és elõállításuk
JP5862560B2 (ja) 2009-05-21 2016-02-16 アメリカン ナショナル レッド クロス レセプター随伴タンパク質（ｒａｐ）、前記の誘導体、模倣体および合成ペプチドによるプリオン増殖の阻害
US8841429B2 (en) * 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
AU2010315133B2 (en) * 2009-11-04 2015-09-10 Novartis Ag Positively charged species as binding reagents in the separation of protein aggregates from monomers
US9162223B2 (en) 2011-12-21 2015-10-20 North Carolina State University Alkaline-stable chromatographic resins
JP6268173B2 (ja) 2012-07-19 2018-01-24 第一三共株式会社 抗Ｓｉｇｌｅｃ−１５抗体
CN103336124B (zh) * 2012-12-11 2015-07-15 武汉工业学院 一种检测朊病毒蛋白(PrPSC)的方法和试剂盒
EP2995621A1 (en) 2014-09-10 2016-03-16 Previpharma AG Ligands and methods for isolating or removing proteins
CA2995204A1 (en) 2015-08-10 2017-02-16 Essenlix Corp. Bio/chemical assay devices and methods for simplified steps, small samples, accelerated speed, and ease-of-use
EP3341724B1 (en) 2015-09-14 2023-10-04 Essenlix Corporation Device and system for collecting and analyzing vapor condensate, particularly exhaled breath condensate, as well as method of using the same
AU2016323062A1 (en) 2015-09-14 2018-04-12 Essenlix Corp. Device and system for analyzing a sample, particularly blood, as well as methods of using the same
JP6667052B1 (ja) 2016-12-21 2020-03-18 エッセンリックス コーポレーション 試料を認証するためのデバイスおよび方法ならびにその使用
CN111246945A (zh) 2017-02-07 2020-06-05 Essenlix公司 压缩开放流测定和使用
CA3053002A1 (en) 2017-02-08 2018-08-16 Essenlix Corp. Bio/chemical material extraction and assay
CN111656155B (zh) 2017-02-08 2024-05-31 上海宜晟生物科技有限公司 用于延迟分析的样品采集和操作
WO2018148461A1 (en) 2017-02-09 2018-08-16 Essenlix Corp. Assay with amplification
WO2018148607A1 (en) 2017-02-09 2018-08-16 Essenlix Corporation Assay using different spacing heights
WO2018148609A2 (en) 2017-02-09 2018-08-16 Essenlix Corporation Colorimetric assays
JP7107953B2 (ja) 2017-02-16 2022-07-27 エッセンリックス コーポレーション テクスチャ表面を用いたアッセイ
EP3406632A1 (en) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Ligands binding to prion protein for use in the treatment of synucleinopathies
US11280706B2 (en) 2017-08-01 2022-03-22 Essenlix Corporation Dilution calibration
CN112689758A (zh) 2017-08-01 2021-04-20 Essenlix公司 检查药物对微生物影响的装置和方法
CN111492222A (zh) 2017-08-01 2020-08-04 Essenlix公司 样品收集、保持和测定
WO2019075415A1 (en) 2017-10-13 2019-04-18 Essenlix Corporation DEVICES AND METHODS FOR AUTHENTICATING MEDICAL ANALYSIS AND USES THEREOF
US11237113B2 (en) 2017-10-26 2022-02-01 Essenlix Corporation Rapid pH measurement
US11609224B2 (en) 2017-10-26 2023-03-21 Essenlix Corporation Devices and methods for white blood cell analyses
US10807095B2 (en) 2017-10-26 2020-10-20 Essenlix Corporation Making and tracking assay card
US11648551B2 (en) 2017-12-12 2023-05-16 Essenlix Corporation Sample manipulation and assay with rapid temperature change
US11510608B2 (en) 2017-12-14 2022-11-29 Essenlix Corporation Devices, systems, and methods for monitoring hair
WO2019140334A1 (en) 2018-01-11 2019-07-18 Essenlix Corporation Homogeneous assay (ii)
US11885952B2 (en) 2018-07-30 2024-01-30 Essenlix Corporation Optics, device, and system for assaying and imaging
JP7376040B2 (ja) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 神経変性疾患におけるバイオマーカー分子の検出方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601398A1 (de) * 1986-01-18 1987-07-23 Fresenius Ag Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
EP0347890B1 (en) * 1988-06-22 1993-03-17 Roussel Morishita Co., Ltd. Amino acid nutrient compositions
WO1991005262A1 (en) * 1989-10-02 1991-04-18 University Of Michigan Bioanalytical detection system
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
IE910713A1 (en) 1990-03-05 1991-09-11 Cephalon Inc Chymotrypsin-like proteases
US6995141B1 (en) * 1990-04-04 2006-02-07 Vertex Pharmaceuticals Incorporated Interleukin 1β protease and interleukin 1β protease inhibitors
US5416013A (en) * 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9024005D0 (en) * 1990-11-05 1990-12-19 British Bio Technology Process for amplifying nucleic acid
JP4233604B2 (ja) * 1991-12-03 2009-03-04 プロセリックス メディスンズ ディベロップメント リミテッド プリオンタンパク質のフラグメント
US5312730A (en) * 1992-05-27 1994-05-17 Ciba Corning Diagnostics Corp. Immune complex transfer with lypophilic bridge
CA2109646C (en) * 1992-11-24 2000-03-07 Gaston O. Daumy Para-nitroanilide peptides
JPH08178926A (ja) * 1994-10-25 1996-07-12 Sumitomo Pharmaceut Co Ltd イムノアッセイプレートおよびその用途
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
AU7142796A (en) * 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
DE69724619T2 (de) * 1996-05-14 2004-07-01 Winnacker, Ernst-Ludwig, Prof. Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
JP2000512131A (ja) * 1996-05-29 2000-09-19 マクギル ユニバーシティー プリオン蛋白結合蛋白およびその使用法
US5808011A (en) 1996-07-01 1998-09-15 Biopure Corporation Method for chromatographic removal of prions
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
JPH10182695A (ja) * 1996-12-27 1998-07-07 Teikoku Seiyaku Co Ltd ｇｐ１２０に対して親和性を有するペプチド
US6221614B1 (en) * 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
GB9710582D0 (en) * 1997-05-22 1997-07-16 Oxford Glycosciences Uk Ltd A method for de novo peptide sequence determination
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
US6750025B1 (en) * 1998-07-09 2004-06-15 V.I. Technologies, Inc. Method of detecting and isolating prion protein and variants thereof
DE19917838A1 (de) * 1999-01-12 2000-07-13 Bundesrepublik Deutschland Let Arzneimittel zur prophylaktischen oder therapeutischen Behandlung von transmissiblen spongiformen Enzephalopathien, Morbus Alzheimer und Corea Huntington und anderen neurodegenerativen Erkrankungen sowie diagnostische Mittel
AU6424300A (en) * 1999-05-27 2000-12-18 Max-Delbruck-Centrum Fur Molekulare Medizin Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
EP1194164B8 (en) * 1999-06-23 2007-03-21 IDEXX Laboratories Inc Prion protein peptides and uses thereof
EP1210110A4 (en) * 1999-06-29 2003-03-19 Univ Mcgill PROTEINS BINDING TO PRION PROTEIN AND THEIR USE
US6261790B1 (en) * 1999-07-15 2001-07-17 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies
WO2001006989A2 (en) * 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
WO2001019867A1 (de) * 1999-09-14 2001-03-22 Memorec Stoffel Gmbh Prionen-verwandtes protein
US6437102B1 (en) * 1999-11-24 2002-08-20 Bayer Corporation Method of separating prions from biological materials
WO2001071042A2 (en) * 2000-03-23 2001-09-27 Pe Corporation (Ny) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
EP1272509A2 (en) * 2000-04-05 2003-01-08 V.I. Technologies, Inc. Prion-binding peptidic ligands and methods of using same
KR20020040676A (ko) * 2000-04-12 2002-05-30 이데이 노부유끼 데이터 전송 방법 및 데이터 전송 장치
GB0009918D0 (en) 2000-04-20 2000-06-07 Rose Keith Covalent capture facilitating purification of polypeptides
US20020155106A1 (en) * 2000-12-01 2002-10-24 Hammond David J. Method of identifying a ligand for a target molecule
US7022486B2 (en) 2001-08-13 2006-04-04 Douglas A. Campbell Peptide sequence tags and method of using same
DE10152677A1 (de) * 2001-10-19 2003-05-08 Aventis Behring Gmbh Antikörper zum spezifischen Nachweis von pathogenen Prionen humanen Ursprungs und damit durchgeführten Nachweisverfahren
JP2003149461A (ja) * 2001-11-12 2003-05-21 Allied Tereshisu Kk 収納装置
EP2317317B1 (en) * 2002-12-03 2014-11-26 North Carolina State University Prion protein ligands and methods of use
PL1615992T3 (pl) * 2003-04-04 2014-03-31 Pathogen Removal And Diagnostic Tech Inc Materiały wiążące białko prionowe i sposoby ich zastosowania
US7510848B2 (en) * 2003-04-04 2009-03-31 North Carolina State University Prion protein binding materials and methods of use
WO2006102099A2 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California ANTIBODIES SPECIFIC FOR HUMAN AND BOVINE PrP

Also Published As

Publication number Publication date
HK1124388A1 (en) 2009-07-10
EP2317317A1 (en) 2011-05-04
CN1739029A (zh) 2006-02-22
NZ540417A (en) 2008-04-30
PT1573323E (pt) 2012-01-10
CN102241741A (zh) 2011-11-16
CN102241741B (zh) 2013-11-13
AU2003302500A1 (en) 2004-06-23
ES2460641T3 (es) 2014-05-14
MXPA05005920A (es) 2006-03-17
PT1953551E (pt) 2014-05-06
CA2836951C (en) 2017-01-10
IL206129A0 (en) 2010-11-30
AU2003302500B2 (en) 2010-04-29
EP1573323A4 (en) 2007-04-04
IL168904A (en) 2010-11-30
JP4485367B2 (ja) 2010-06-23
ATE529744T1 (de) 2011-11-15
IL200468A (en) 2012-06-28
CN102297798A (zh) 2011-12-28
WO2004050851A3 (en) 2005-01-27
HK1088948A1 (en) 2006-11-17
NZ560410A (en) 2008-12-24
EP2317317B1 (en) 2014-11-26
CN1739029B (zh) 2011-06-22
EP2312318B1 (en) 2014-10-08
PT2317317E (pt) 2015-03-02
CN102297798B (zh) 2015-11-18
WO2004050851A2 (en) 2004-06-17
DK2317317T3 (en) 2015-03-02
EP1573323A2 (en) 2005-09-14
HK1157010A1 (en) 2012-06-22
ES2527408T3 (es) 2015-01-23
US7863411B2 (en) 2011-01-04
CA2836951A1 (en) 2004-06-17
US20040229280A1 (en) 2004-11-18
US9678085B2 (en) 2017-06-13
EP1573323B1 (en) 2011-10-19
IL206129A (en) 2013-11-28
AU2010201499A1 (en) 2010-05-06
EP2312318A1 (en) 2011-04-20
NZ572892A (en) 2010-03-26
EP1953551B1 (en) 2014-02-19
IL200468A0 (en) 2011-07-31
US20140206021A1 (en) 2014-07-24
DK2312318T3 (en) 2015-01-12
ES2375958T3 (es) 2012-03-07
CA2507936A1 (en) 2004-06-17
US20080268474A1 (en) 2008-10-30
EP1953551A3 (en) 2009-03-18
MX337569B (es) 2016-03-09
PT2312318E (pt) 2015-01-14
CA2507936C (en) 2014-02-25
US8604161B2 (en) 2013-12-10
EP1953551A2 (en) 2008-08-06
DK1953551T3 (da) 2014-05-12
AU2010201499B2 (en) 2013-02-07
JP2006509013A (ja) 2006-03-16
ES2531926T3 (es) 2015-03-20
DK1573323T3 (da) 2012-01-23

Similar Documents

Publication Publication Date Title
HK1157009A1 (en) Prion protein ligands and methods of use
DK1615992T3 (da) Prionproteinbindende materialer og fremgangsmåder til anvendelse
TNSN07136A1 (en) Prion protein binding materials and methods of use
TW200621798A (en) Sequential protein isolation and purification schemes by affinity chromatography
BR0311471A (pt) anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero
DE602006021395D1 (de) Screening-verfahren
WO2007008071A3 (en) Method for detecting peptides comprising a cross-beta structure
DE602006013143D1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
ATE525462T1 (de) Proteomanalyseverfahren für phosphoryliertes protein
WO2005036123A3 (en) Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
WO2006056438A3 (de) Protein-biochip zur validierung von bindern
ATE487791T1 (de) Verfahren und formulierung zur extraktion von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien
ATE533055T1 (de) Verfahren zum screenen mithilfe von konformationsempfindlichen peptiden
ATE547161T1 (de) Verfahren zur quantitativen bestimmung von poloxameren
DE602004011228D1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
ATE354095T1 (de) Verfahren zur detektion von prp unter verwendung ein makrozyklischen ligand
DE60218848D1 (de) Verfahren zur trennung und/oder zum nachweis und/oder zur identifizierung und/oder zur quantifizierung von prionproteinen
DK1604209T3 (da) Screeningsassay
WO2007060373A3 (fr) Procede d'identification du genotype en position 171 de la proteine prion d'ovin ainsi que trousses de mise en oeuvre de ce procede
ATE422674T1 (de) Verfahren zur analyse n-terminaler proteinaddukte
DE60325857D1 (de) Verfahren zur serologischen diagnose

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231202